ArticleJournal of clinical laboratory analysis2019
Epidemiological survey of antinuclear antibodies in healthy population and analysis of clinical characteristics of positive population.
Article in Journal of clinical laboratory analysis, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 44 citations in OpenAlex.
- Autoantibody-positive healthy individuals with lower lupus risk display a unique immune endotype.The Journal of allergy and clinical immunology · 2020Trial
- Molecular classification of primary Sjögren's syndrome based on salivary gland omics.Arthritis research & therapy · 2026Article
- Autoantibody Ordering Patterns Across a Tertiary Hospital: A Retrospective Audit.Open access rheumatology : research and reviews · 2026Article
- The implication of anti-Ro60 with or without anti-Ro52 antibody in patients with systemic lupus erythematosus.Rheumatology (Oxford, England) · 2025Article
- Prevalence and association testing of antinuclear antibodies and inflammatory bowel disease in Taiwan.PeerJ · 2025Article
- Identifying antinuclear antibody positive individuals at risk for developing systemic autoimmune disease: development and validation of a real-time risk model.Frontiers in immunology · 2024Article
- A single-centre study on abnormal antinuclear antibodies in children caused by intravenous infusion of gamma globulin.Frontiers in immunology · 2024Article
- Autoantibodies in COVID-19: implications for disease severity and clinical outcomes.Frontiers in immunology · 2024Review
- Potential Immunoregulatory Mechanism of Plant Saponins: A Review.Molecules (Basel, Switzerland) · 2023Review
- Discriminating between Homogeneous (AC-1) and Dense Fine Speckled (AC-2) Antinuclear Antibody Patterns: Re-Evaluation of Immunofluorescence Imaging.Biomedicines · 2023Article
- Article
- The Diagnosis, Treatment, and Clinical Sequelae of Sjogren's Syndrome in a Pediatric Patient: A Case Report.Cureus · 2023Article
- The diagnostic challenge of patients with anti-U1-RNP antibodies.Rheumatology international · 2023Article
- Myositis-Specific and Myositis-Associated Antibodies in Fibromyalgia Patients: A Prospective Study.Biomedicines · 2023Article
- Comparison of Indirect Immunofluorescence and Enzyme Immunoassay for the Detection of Antinuclear Antibodies.Cureus · 2022Article
- Diagnostic Value of Anti-Nuclear Antibodies: Results From Korean University-Affiliated Hospitals.Journal of Korean medical science · 2022Article
- HCV Infection Alters Salivary Gland Histology and Saliva Composition.Journal of dental research · 2022Article
- Prevalence of antinuclear antibodies in inflammatory bowel disease and seroconversion after biological therapy.Therapeutic advances in gastroenterology · 2022Article
- The Prevalence and Clinical Relevance of the DFS Immunofluorescence Staining Pattern in a Large ANA-Positive Cohort.Frontiers in medicine · 2022Article
- Antinuclear Antibody Profiling in Patients of a Tertiary Care Centre in Central India.Indian journal of clinical biochemistry : IJCB · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundIn China, the incidence of autoimmune diseases is gradually increasing. To decrease the misdiagnosis rate of autoimmune diseases, we conducted an epidemiological investigation about the presence of antinuclear antibody (ANA) in healthy populations and analyzed the clinical characteristics of healthy population with both high titer of ANA and positive anti-SSA and AMA-M2.
methodsSerum ANA titers were detected by indirect immunofluorescence (IIF), and other 15 types of ANA-specific antibodies were detected by line immunoassays.
resultsIn 25 110 individuals for routine examination, the positive rate of ANA titer >1:100 was 14.01%, of which the positive rate of female (19.05%) was higher than that of male (9.04%; P < 0.01). The positive rate of ANA titer >1:320 was 5.93%, of which the positive rate of female (8.68%) was higher than that of male (3.21%; P < 0.01). The specific antibodies were detected in 1489 of ANA-positive people with titer >1:320, and the top three detected antibodies were anti-Ro-52 (212), AMA-M2 (189), and anti-SSA (144). The abnormal rate of blood routine test, liver function test, and other clinical indicators in AMA-M2-positive population was significantly different from those in the control group. The abnormal rate of blood routine test, liver function test, and immune index in anti-SSA-positive population was higher than those in control group.
conclusionThere was a high prevalence of ANA positive in healthy population. To avoid misdiagnosis, those who had symptoms of abdominal discomfort, pruritus, or fatigue with abnormal results of blood routine and liver function test should be examined for ANA, AMA-M2, anti-SSA as early as possible.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.